Sleep is a critical physiological process that allows the body to rest, repair and rejuvenate and it has profound implications for systemic health, particularly the cardiovascular system. Along with ...

Alpha-Gal Syndrome (AGS) is an underrecognized, tick-borne allergic condition with emerging relevance in cardiovascular medicine. Sensitization to galactose-α-1,3-galactose (alpha-gal), a ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

A newly released ACC Expert Consensus Decision Pathway (ECDP) focused on the clinical assessment, management and trajectory of patients hospitalized with heart failure (HF) includes revisions to the ...

As obesity continues to drive cardiovascular risk, the ACC has released two new guidance documents to support clinicians: Concise Clinical Guidance (CCG) on the medical management of obesity and a ...

The Global Heart Attack Treatment Initiative (GHATI) is dedicated to collaborating, collecting and sharing data, and utilizing tools to improve acute myocardial infarction (AMI) care for your MI ...

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

A new nasal spray form of bumetanide may reduce the tissue swelling caused by heart failure (HF) as effectively as the standard oral and intravenous formulations of the loop diuretic, based on ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

The ACC has issued guidance for the diagnosis and management of acute myocarditis in adult patients, delivering a streamlined decision-making framework that reflects recent advancements in clinical ...

In-hospital initiation of dapagliflozin in patients hospitalized for acute heart failure (HF) did not significantly reduce the short-term risk of worsening HF or death, based on findings from the DAPA ...

Asundexian was associated with a higher incidence of stroke or systemic embolism, but less major bleeding, compared with apixaban among patients with atrial fibrillation (AFib) who were at high risk ...